促肾上腺皮质激素4-9类似物（Org2766）对阿尔茨海默病患者某些脑脊液参数的影响。
The effect of ACTH4-9 analog (Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease.
作者信息
Jolkkonen J T, Soininen H S, Riekkinen P J
出版信息
Life Sci. 1985 Aug 19;37(7):585-90. doi: 10.1016/0024-3205(85)90424-2.
In a double-blind, placebo-controlled study, the central nervous system effects of an ACTH4-9 analog, Org2766 (40 mg/day), in Alzheimer's disease were assessed by measuring cerebrospinal fluid parameters during 6 months' treatment. Somatostatin-like immunoreactivity and cholinesterase activity, which are known to be reduced in cerebrospinal fluid of Alzheimer patients compared with controls, did not change during treatment. As a marker of noradrenergic and dopaminergic systems, we measured dopamine-beta-hydroxylase and homovanillic acid, but both levels were static. These results suggest that Org2766 did not interact with the transmitter systems, which are thought to be disturbed in Alzheimer's disease.
在一项双盲、安慰剂对照研究中，通过在6个月治疗期间测量脑脊液参数，评估了促肾上腺皮质激素4-9类似物Org2766（40毫克/天）对阿尔茨海默病中枢神经系统的影响。与对照组相比，已知阿尔茨海默病患者脑脊液中降低的生长抑素样免疫反应性和胆碱酯酶活性在治疗期间没有变化。作为去甲肾上腺素能和多巴胺能系统的标志物，我们测量了多巴胺-β-羟化酶和高香草酸，但两者水平均无变化。这些结果表明，Org2766与被认为在阿尔茨海默病中受到干扰的递质系统没有相互作用。
Zotero 插件